Turning Brazil’s Ophthalmology potential into business strategy for global companies

As your premium bridge for global ophthalmology biotechs, OBBA delivers 20+ years of proven, hands-on expertise in clinical studies, market entry, growth, and launch in Brazil — empowering innovation in eye care for Brazilian patients and professionals.

Designed for Global Teams

Built for biotechs, pharma and MedTech leaders making international investment decisions.

Integrated Science & Business Vision

Clinical insight, market intelligence, and commercial strategy in one integrated view.

High-level Access to the Ophtha Ecosystem

Stakeholders, KOLs, investigators, institutions, and market dynamics — mapped and engaged through exclusive, high-level networks.

Brazil is one of the most promising ophthalmology markets in the world, with a highly admixed population over 200 million people and a growing demand for Ophtha care. Yet the country presents a challenging regulatory environment, fragmented healthcare system, and unique stakeholder dynamics.

Thus, Brazil is crucial for a global strategy - but a tailor-made approach is mandatory in order to translate Brazil’s scientific, clinical, and commercial reality into structured business strategy.

OBBA exists to bridge that gap.

→ Explore Who we are

What We Unlock?

We support strategic decision-making across the full ophthalmology value chain, including:

  • Launch and growth strategy
  • Market entry (BP) and go-to-market models
  • Clinical development, trial oversight and Support
  • Broad stakeholder identification and engagement
  • Local Patient Journey mapping
  • Ad Board, IMs and Mini summits organization

All delivered with local depth and global business logic.

→ Explore What We Do

Why OBBA

What makes OBBA different is not a single capability — it’s the integration of:

  • Over 20 years of deep Ophthalmology expertise
  • Across all Ophtha subspecialties
  • Executive leadership in multiple Big Pharma and MedTechs
  • Trusted, long-standing relationships with Medical Societies and KOLs
→ Why Global Teams Choose OBBA

Every strategic market decision starts with clarity.

Brazil is a must have on your plans. We would be glad to start a conversation and show you why.

→ Contact OBBA

Who We Are?

Our Founders' Proven Leadership in Ophthalmology

OBBA is founded on over 20 years of hands-on leadership in the pharma and medical devices sectors, with a deep focus on Ophthalmology.

Rogerio Mauad, our founder focused on medical, clinical and strategic development, built his career across global pharmaceutical organizations such as Novartis and Roche, combining clinical research experience in Ophthalmology with senior Medical Affairs leadership. His ability to translate complex clinical science into structured business decisions directly shapes OBBA's medical strategy and stakeholder engagement approach.

Tiago Calvente, our founder focused on market and business development, has driven sales, marketing, and team strategies for global leaders like Roche, J&J Vision, Carl Zeiss, Alcon and Novartis. His patient-centric approach — emphasizing high-performance teams, product launches, and market access — directly informs OBBA's services, bridging international companies to Brazil's dynamic eye care ecosystem.

Rogério Mauad

Rogério Mauad

Founding Partner, Strategy & Medical Affairs

Rogério Mauad is a senior Medical Affairs and strategy leader with 15+ years of experience in the pharmaceutical industry, with a primary focus on Ophthalmology and relevant exposure across Immunology, Neurology, Cardiology, and Respiratory diseases. His career uniquely integrates Clinical Research, Medical Affairs leadership, early pipeline strategy, product planning, and launch excellence.

He most recently served as Head of Medical Affairs at Roche Brazil, leading the Ophthalmology and Immunology teams. In this role, he drove multiple ophthalmology pre-launch and launch strategies, coordinated a national clinical trial with 15+ sites, and led a multiregional fellows' training program across more than 10 institutions, strengthening medical education and real-world evidence generation nationwide.

Prior to Roche, Rogério spent over 11 years at Novartis, holding progressively senior roles across Medical Affairs, Marketing, and New Products Strategy. As Senior New Products Manager and acting Head of Medical Affairs for Gene Therapy, he created and led a new strategic unit supporting early and late-stage pipeline assets and coordinated cross-functional planning across multiple therapeutic areas. Earlier, he led medical and marketing strategies in Ophthalmology, working closely with Retina KOLs nationwide.

Rogério's foundation in Ophthalmology was built as a Clinical Research Coordinator at Federal University of São Paulo (UNIFESP), where he coordinated 12+ clinical studies in Ophthalmology, managing regulatory submissions, site operations, patient recruitment, and GCP compliance — a background that still defines his strategic perspective today.

Beyond his corporate career, Rogério is also a recognized entrepreneur and national reference in Medical Affairs education in Brazil. As Founder and Executive Director of PharmaPrime, he built one of the country's most established platforms for Medical Affairs, MSL, and scientific engagement training, personally leading the development of hundreds of MSLs and medical leaders now working across major pharmaceutical and biotech companies in Latin America.

Rogério holds an MBA in Business Management, a Specialization in Clinical Research from Harvard Medical School, a Master's degree in Science, and a Bachelor's degree in Biomedical Sciences. He is fluent in English, Portuguese, and Spanish.

At OBBA, Rogério brings together deep Ophthalmology and Retina expertise, senior-level Medical Affairs leadership, first-hand clinical research experience, and a strong entrepreneurial track record in capability building, enabling global companies to make high-confidence strategic decisions in one of the world's most complex and promising ophthalmology markets.

Link to Rogério's LinkedIn Profile
Tiago Calvente

Tiago Calvente

Founding Partner, Strategy, Market & Business Development

Tiago Calvente is a senior Strategy and Business leader with 25+ years of experience in the ophthalmology market, building his career across sales leadership, marketing strategy, market access, and business development within global pharmaceutical, surgical, and diagnostic companies.

He began his career with over a decade in commercial leadership roles at Alcon and Novartis, where he held progressively senior positions in sales management, including five years as Regional Sales Manager for Northeast Brazil. During this period, he led high-performance teams, doubled revenue through innovative product launches, and achieved market share leadership in Glaucoma and Dry Eye across both private and public markets.

Tiago later transitioned into Senior Marketing and Portfolio Leadership roles at Novartis, Alcon, Johnson & Johnson Vision and Carl Zeiss. Across these organizations, he led multiple successful launches and large portfolio strategies spanning Glaucoma, Retina, Dry Eye, Cataract, Contact Lenses, surgical and diagnostic platforms. His experience includes:

  • Development of access strategies from scratch for new surgical devices
  • Large-scale launch orchestration, including events with 1,000+ HCPs
  • Direct-to-consumer (DTC) campaigns, including national presbyopia initiatives
  • Local distributor models and LATAM partnership strategies with global companies

From 2022 to 2024, Tiago served as Ophthalmology Squad Lead at Roche Brazil, where he was responsible for the strategic entry of Roche into the Brazilian ophthalmology market with Vabysmo, structuring the go-to-market model, stakeholder strategy, and launch execution.

He has also acted as Expansion Partner at Grupo Hospital Opty, leading growth initiatives, operational scaling, and strategic partnerships for one of Brazil's leading ophthalmology hospital networks.

More recently, Tiago has operated as an Independent Consultant for Ophthalmology companies and clinics, advising on:

  • Market research and opportunity assessment
  • Commercial team capability development
  • Customized marketing narratives aligned with Brazilian regulatory frameworks

He is also the Founder of Blink Care, a healthtech focused on innovative dry eye management solutions, which he developed from concept to early commercialization.

Tiago holds a Bachelor's degree in Business Administration, a Specialization in Marketing, and MBAs in Business Economics and Hospital Administration in Ophthalmology from leading institutions including IPEPO / UNIFESP and FGV.

At OBBA, Tiago brings deep commercial execution, market access strategy, portfolio leadership, and go-to-market design expertise, ensuring that global ophthalmology innovations are translated into scalable, compliant, and high-impact business models for Brazil.

Link to Tiago's LinkedIn Profile

What We Do

Our Comprehensive Services

With over 20 years of hands-on expertise in Brazil's ophthalmology landscape, OBBA bridges global biotechs to local success. We offer tailored consulting in two core pillars: facilitating clinical studies to accelerate innovation and driving business strategies for seamless market entry. Our services are designed to navigate regulatory, stakeholder, and market challenges, ensuring your technologies reach Brazilian patients and professionals efficiently.

Empower your global trials with localized expertise, securing Brazilian sites and KOLs to strengthen your pipeline and presence in this emerging market.

  • Clinical Trial Protocol Feasibility & Local Operations Support: Assess protocol viability in Brazil's regulatory environment and provide end-to-end support for site selection, operations, and patient recruitment to ensure smooth execution.
  • KOL & HCP Engagement (Pre- and Post-Approval): Build strategic relationships with Key Opinion Leaders (KOLs) and Healthcare Professionals (HCPs) through advisory boards, investigator meetings, and pre-regulatory engagement programs—crafting targeted interactions to align your innovation with local needs and gather actionable insights.
  • Patient Journey Mapping & Regulatory Pre-Submission Analyses: Identify Brazil-specific patient pathways in ophthalmology and conduct thorough pre-submission reviews to optimize trial design, compliance, and feasibility, minimizing delays.
  • Thematic Mini-Summits & Local Societies Engagement: Organize focused events on disease pathways, treatment trends, and funding opportunities, while engaging medical societies to foster collaborations and enhance trial visibility.

From market entry to go-to-market execution, we synthesize Brazil's ophthalmology ecosystem—covering payers, competitors, and access—to deliver actionable plans that drive sustainable growth and assertive positioning strategy.

  • Stakeholder & Landscape Mapping: Conduct broad mapping of stakeholders (beyond physicians, including payers, hospitals, and institutions), engagement plans, Patient Journey gaps and opportunities and comprehensive landscape analysis (disease trends, market dynamics) to inform your Brazil strategy.
  • Business Planning & Go-to-Market Models: Develop customized business plans, pricing studies*, competitor benchmarks, and GTM frameworks, including customer-facing structures, territory allocation, and multichannel/DOL strategies for efficient scaling.
  • Market Research & Insights Gathering: Perform in-depth research on local access scenarios, distributor mapping, and big players (hospital groups, teaching institutions), culminating in tailored business plan and congress opportunity identification.
  • Marketing & Narrative Adaptation: Customize scientific narratives, marketing claims, and campaigns to comply with Brazilian regulations, while building team capabilities in science and local ophthalmology market dynamics.
  • Partnership & JV Formation: Facilitate joint ventures, licensing deals, and local distributor partnerships, with negotiation support to align global biotechs with Brazilian entities.

Who We Work With

OBBA partners with global teams operating at different stages of the ophthalmology value chain, including:

Global Biotechs

Preparing first market entry, clinical expansion, or strategic partnering in Brazil.

Pharmaceutical and MedTech Companies

With established or emerging ophthalmology portfolios seeking strategic refinement, expansion, or launch excellence.

Senior Leadership Teams

Across Business Development, Strategy, Medical Affairs, and General Management.

We operate as a strategic extension of global leadership teams, not as a transactional service provider.

Our Role

We don't replace internal teams.

We strengthen strategic decision-making where local complexity, scientific depth, and business execution intersect.

Why Brazil

One of the Most Promising — and Underestimated — Ophthalmology Markets in the World

Brazil is one of the largest healthcare markets globally, with over 210 million people, rapid population aging, and a structurally growing burden of retinal and ocular diseases. Yet, despite its scale and scientific relevance, Brazil remains underexplored by many global ophthalmology innovators.

This combination of market size, genetic diversity, disease burden and healthcare complexity makes Brazil a uniquely powerful environment for both clinical development and commercial expansion.

Brazil’s Core Strategic Value: Scale, Diversity and Demand

1. Scale

  • One of the largest patient populations worldwide
  • High and growing prevalence of retinal diseases, such as Diabetic Macular Edema (DME) and Age-Related Macular Degeneration (AMD), Glaucoma, Dry Eye, Cataract, Rare diseases and others
  • Universal health coverage by the public system - known by its complexity but with a consistent history of incorporating new and advanced technologies not limited to Ophthalmology, such as Spinal Muscular Atrophy, Hemophilia, Duchenne Muscular Dystrophy, among others
  • 25% of the population assisted by private insurance, also with access to new technologies*

2. Genetic and Clinical Diversity

Brazil's highly admixed population — with European, African and Indigenous ancestries — creates one of the most genetically diverse populations studied to date.

For Ophthalmology, this means:

  • Broader representation of real-world patients
  • Unique inflammatory, vascular and genetic profiles
  • Greater external validity for global clinical programs
  • A natural laboratory for precision medicine, biologics and gene therapies

3. Structural Demand

The combination of:

  • Demographic aging
  • Diabetes growth
  • Limited early screening coverage

Creates a structural, long-term demand for retinal diagnostics and therapies that is independent of economic cycles.

A Dual Market: Public Volume and Private Value

Public System (SUS)

Universal coverage. Concentrates volume. High clinical complexity.

Private Market

~25% of population. High healthcare spending. Faster adoption of premium tech.

Brazil is extremely attractive in volume — but its value is unlocked only through a carefully designed scientific, access and positioning strategy.

Brazil as a Retina Clinical Development Powerhouse

Brazil has become increasingly relevant for:

  • Anti-VEGF programs
  • Inflammatory and uveitis pipelines
  • Gene and cell therapies
  • Long-acting delivery platforms and devices

Key advantages include:

  • High patient volume
  • Investigators experienced with advanced therapies
  • High-complexity public and private centers
  • Real-world clinical heterogeneity that stress-tests innovations beyond “perfect” trial populations

Regulatory timelines can be more variable than in some regions, but once approved, recruitment can be highly competitive in the right sites — especially when scientific alignment with local leaders happens early.

An Opportunity with Asymmetric Risk

Brazil is not a “plug-and-play” market.

Its:

  • Fragmented healthcare structure
  • Regional heterogeneity
  • Regulatory complexity
  • Off-label treatment dynamics
  • Public vs. private asymmetries

Create an asymmetric risk profile:

  • Entering without strategy → high execution risk
  • Entering with strategic clarity → structural competitive advantage

This is precisely why Brazil rewards:

  • Science-driven positioning
  • Early KOL engagement
  • Thoughtful market access design
  • Realistic volume and revenue assumptions

Why Most Global Teams Misread Brazil

The most common strategic mistakes include:

  • Overestimating private market speed
  • Underestimating public system complexity
  • Ignoring off-label competitive dynamics
  • Misjudging regional differences
  • Delaying scientific credibility building

Brazil is complex because it is continental, heterogeneous and asymmetric.

Where OBBA Fits In

OBBA exists to transform Brazil from:

A high-risk unknown into a structured strategic option.

We help global teams:

  • Understand true clinical and market potential
  • Build realistic entry and growth hypotheses
  • Design science-first positioning strategies
  • Navigate public and private dynamics coherently
  • Translate Brazilian complexity into executive-level decisions

Brazil is not a bet. It is a strategy — when done right.

Brazil must be on your strategic radar for Ophthalmology, and OBBA helps you move from intuition to structured decision-making.

→ Start a Strategic Conversation

Why Choose OBBA?

In a complex market like Brazil's ophthalmology sector, choosing the right partner means the difference between delays and dominance. OBBA stands out with 20+ years of proven, hands-on expertise—not theoretical advice, but real-world implementation that bridges global biotechs to local success. We understand your pain points: regulatory hurdles, stakeholder alignment, and market navigation. Here's why we deliver value to biotech and Big Pharma leaders:

Unmatched Hands-On Experience in Ophthalmology

Our founders bring over two decades of direct involvement in Brazil's eye care ecosystem—from clinical trials to market launches—ensuring strategies grounded in practical insights, not academia.

Proven Senior Leadership Across Global Pharma & MedTech

OBBA is led by partners who have held senior leadership positions across multiple global pharmaceutical and MedTech organizations like Alcon, J&J, Novartis, Roche and Zeiss. We bring first-hand experience from the decision side of the table — not as external observers, but as former owners of the strategy and execution.

Exclusive Focus on Ophthalmology

We are not a generalist consultancy. OBBA is purpose-built for ophthalmology innovation — allowing for deeper insight, sharper strategic judgment, and higher-quality decisions.

Your Strategic Bridge to Brazil

As the premier gateway for international companies, we leverage deep local networks (KOLs, payers, hospitals) and global connections to facilitate seamless integration.

Premium, Personalized Partnership

We treat every client as a long-term ally, tailoring solutions to your specific goals with ethical, compliant strategies. Backed by our rare expertise, we build trust through transparent communication and rapid value delivery—empowering you to lead in Brazil's booming ophthalmology market.

We are not a volume consultancy: we are a high-trust, high-impact strategic partner where you will have direct access to our advisors and no junior dilution.

Your bridge to Brazil starts here.

Partner with OBBA: Let's Discuss Your Brazil Strategy

Testimonials

“A creative powerhouse on his own, Tiago is a selfless contributor with an outstanding flair for innovation. This adds the right amount of spice to any project he participates in. Diligent on his deliveries, his commercial experience combined with strong marketing fundamentals is a guarantee of focus on the result and adds balance to any marketing team.“

Rodrigo Guarana

General Manager, Chroma UK

“Rogerio is one of the most collaborative persons I have ever worked with. He has a innovative mindset, an open communication and a fantastic ability to motivate people around him. Working with him was a privilege and I am looking forward to our paths to cross again.“

Fernanda Boulos

Chief Scientific Officer, Inst Butanta

Contact Us

Get in touch

We are here to answer any questions you may have.

LinkedIn: OBBA LinkedIn